Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+ cell homing to the infarcted heart.

Stromal-derived factor 1alpha (SDF-1alpha) is a key stem cell homing factor that is crucial for mobilization of stem cells from bone marrow to peripheral blood and subsequent engraftment to the tissue of diseased organs. It has been reported that SDF-1alpha is transiently over-expressed in ischemic myocardium. Therefore, there may be a limited time window after acute myocardial infarction (AMI) during which stem cells are recruited to injured myocardium for repair. This study aimed at investigating whether controlled release of SDF-1alpha via a novel conjugated poly(ethylene glycol) (PEG) (PEGylated) fibrin patch at the infarct site would increase the rate of stem cell recruitment and offer potential therapeutic benefits. Recombinant mouse SDF-1alpha was covalently bound to the PEGylated fibrinogen as evidenced by immunoprecipitation and western blotting. The PEGylated fibrinogen, bound with recombinant mouse SDF-1alpha, was mixed with thrombin to form the PEGylated fibrin patch. The release kinetics of SDF-1alpha were detected in vitro using enzyme-linked immunosorbent assay. Using a mouse AMI model produced by a ligature on the left anterior descending coronary artery, a PEGylated fibrin patch bound with SDF-1alpha (100 ng) was placed on the surface of the infarct area of the left ventricle. Infarct size, left ventricular (LV) function, and the percentage of sca-1(+)/c-kit(+) cells within the infarct area were measured at days 7, 14, and 28 after AMI. In vitro results showed that SDF-1alpha was successfully bound to the PEGylated fibrin patch and can be released from the patch constantly for up to 10 days. Two weeks after infarction, the myocardial recruitment of c-kit(+) cells was significantly higher in the group treated with the SDF-1alpha PEGylated fibrin patch (n = 9) than in the AMI control group (n = 10) (p < 0.05; 11.20 +/- 1.71% vs. 4.22 +/- 0.96%, respectively). At day 28 post-AMI, unlike the control group, the group with the SDF-1alpha-releasing patch maintained stable release of SDF-1alpha concurrent with additional stem cell homing. Moreover, LV function was significantly better than in the control group. These data demonstrate that the PEGylated fibrin patch based SDF-1alpha delivery can improve the rate of c-kit(+) cell homing and improve LV function in hearts with postinfarction LV remodeling.

[1]  D. Torella,et al.  Adult Cardiac Stem Cells Are Multipotent and Support Myocardial Regeneration , 2003, Cell.

[2]  D. Émilie Stromal Cell‐Derived Factor 1 (SDF‐1) , 2002 .

[3]  D. Link,et al.  Cytokines and stem cell mobilization for autologous and allogeneic transplantation. , 2004, Current hematology reports.

[4]  Jianyi(Jay) Zhang,et al.  Autologous stem cell transplantation for myocardial repair. , 2004, American journal of physiology. Heart and circulatory physiology.

[5]  M. Ballmaier,et al.  Haematopoietic stem cells improve cardiac function after infarction without permanent cardiac engraftment , 2005, European journal of heart failure.

[6]  J. Teruya-Feldstein,et al.  Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial , 2005, Bone Marrow Transplantation.

[7]  Michael Lill,et al.  Stem cell transplantation for myocardial infarction? , 2004, Reviews in cardiovascular medicine.

[8]  Kojima Structure and function , 2005 .

[9]  A. From,et al.  The Role of the Sca‐1+/CD31− Cardiac Progenitor Cell Population in Postinfarction Left Ventricular Remodeling , 2006, Stem cells.

[10]  Shokei Kim,et al.  Transmitral inflow pattern assessed by Doppler echocardiography in angiotensin II type 1A receptor knockout mice with myocardial infarction. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[11]  J. Juarez,et al.  Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. , 2004, Current pharmaceutical design.

[12]  S. Jalkanen,et al.  Stromal Cell-Derived Factor 1 (CXCL12) Induces Human Cell Migration into Human Lymph Nodes Transplanted into SCID Mice1 , 2002, The Journal of Immunology.

[13]  Yan Huang,et al.  Stromal Cell–Derived Factor-1α Plays a Critical Role in Stem Cell Recruitment to the Heart After Myocardial Infarction but Is Not Sufficient to Induce Homing in the Absence of Injury , 2004, Circulation.

[14]  K. Malcolm,et al.  Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. , 2004, Blood.

[15]  K. Pillarisetti,et al.  Cloning and Relative Expression Analysis of Rat Stromal Cell Derived Factor-1 (SDF-1): SDF-1 α mRNA Is Selectively Induced in Rat Model of Myocardial Infarction , 2001, Inflammation.

[16]  A. Sun,et al.  Time course of myocardial stromal cell–derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction , 2005, Basic Research in Cardiology.

[17]  Y. Tang,et al.  Mobilizing of haematopoietic stem cells to ischemic myocardium by plasmid-mediated stromal-cell-derived factor-1α treatment , 2005, Regulatory Peptides.

[18]  Y. Gazitt Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific anti , 2004, Leukemia.

[19]  Laura Suggs,et al.  A PEGylated fibrin patch for mesenchymal stem cell delivery. , 2006, Tissue engineering.

[20]  S. Rafii,et al.  The Regulation of Hematopoietic Stem Cell and Progenitor Mobilization by Chemokine SDF-1 , 2003, Leukemia & lymphoma.

[21]  D. Torella,et al.  Cardiac Stem Cells Possess Growth Factor-Receptor Systems That After Activation Regenerate the Infarcted Myocardium, Improving Ventricular Function and Long-Term Survival , 2005, Circulation research.

[22]  M. Goodell,et al.  Phenotype and hematopoietic potential of side population cells throughout embryonic development. , 2003, Blood.

[23]  J. Hata,et al.  In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells. , 2003, Experimental cell research.

[24]  M. Pesce,et al.  SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. , 2004, Blood.

[25]  W. Saltzman,et al.  Synthesis and biological activity of polyethylene glycol-mouse nerve growth factor conjugate. , 1999, Bioconjugate chemistry.

[26]  Meijing Wang,et al.  Stem Cell Transplantation as a Therapeutic Approach to Organ Failure1 , 2005 .

[27]  L. Field,et al.  Cellular therapies for myocardial infarct repair. , 2002, Cold Spring Harbor symposia on quantitative biology.

[28]  M. Rudnicki,et al.  Myogenic specification of side population cells in skeletal muscle , 2002, The Journal of cell biology.

[29]  J. Saffitz,et al.  Extracardiac Progenitor Cells Repopulate Most Major Cell Types in the Transplanted Human Heart , 2005 .

[30]  P. Collin‐Osdoby,et al.  Stromal Cell‐Derived Factor‐1 (SDF‐1) Recruits Osteoclast Precursors by Inducing Chemotaxis, Matrix Metalloproteinase‐9 (MMP‐9) Activity, and Collagen Transmigration , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  M. Ratajczak,et al.  Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury. , 2004, Blood cells, molecules & diseases.

[32]  David A. Williams,et al.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts , 2004, Nature.

[33]  M. Harmsen,et al.  Signaling factors in stem cell-mediated repair of infarcted myocardium. , 2005, Journal of molecular and cellular cardiology.

[34]  I. Weissman,et al.  Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium , 2004, Nature.